500293-53-8

Upstream product

• 244768-32-9 4-[(4-chloro-2-pyrimidinyl)amino]benzonitrile 
• 3095-47-4 4-amino-3,5-dimethylbenzoic acid ethyl ester 
• 823786-21-6 4-[4-(4-hydroxymethyl-2,6-dimethylphenylamino)pyrimidin-2-ylamino]benzonitrile 
• 708254-90-4 4-[2-(4-cyanophenylamino)pyrimidin-4-ylamino]-3,5-dimethylbenzoic acid ethyl ester 

Downstream Products

• 500289-32-7 C₂₅H₃₁N₇ 
• 500287-80-9 4-[4-(4-cyanomethyl-2,6-dimethyl-phenylamino)-pyrimidin-2-ylamino]-benzonitrile 
• 741256-94-0 C₂₆H₂₂N₆ 

Relevant academic research and scientific papers

Pharmaceutical compositions comprising a basic drug compound, a surfactant, and a physiologically tolerable water soluble acid

The invention provides a novel pharmaceutical composition comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base characterized in that the acid respectively base:drug compound ratio is at least 1:1 by weight.

Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1

This paper reports the synthesis and the antiviral properties of new diarylpyrimidine (DAPY) compounds as nonnucleoside reverse transcriptase inhibitors (NNRTIs). The synthesis program around this new DAPY series was further optimized to produce compounds displaying improved activity against a panel of eight clinically relevant single and double mutant strains of human immunodeficiency virus type 1 (HIV-1).